EDX Medical Group’s Post

📉 While clinical trial endpoints for evaluating a new medicine for cancer frequently include survival and tumour response, clinical trials for diagnostic tests need to show how accurate the tests are in identifying whether a condition or disease is present. 🔍 There are several measures of diagnostic accuracy. The measures are complementary to one another and each addresses different aspects of diagnosis. In this post, I show with an example the difference between two important and frequently reported measures - sensitivity and specificity. #diagnostics       #medtech           #marketaccess #healtheconomics #freelancewriter #medcomms

“Medical science has proven time and again that when the resources are provided, great progress in the treatment, cure, and prevention of disease can occur.” Michael J. Fox Medical alert!!! There is nothing more painful to a #primary care physician than to deliver a cancer diagnosis to a patient who didn’t get a screening test for cancer Very excited about the new CRC ( colorectal cancer) blood test cfDNA In a study published recently in the New England Journal of Medicine researchers found that a blood test known as a cell-free DNA blood-based test or cfDNA test was able to detect colorectal cancer in 83% of patients who had the disease. The study was funded by Guardant Health. Why do we care? CRC is the second leading cause of cancer-related deaths worldwide. Although It predominantly affects older individuals aged 50 and above, the rates are rising in young people. Black people with early onset colorectal cancer are more likely to be diagnosed younger and at a more advanced stage We can reduce the impact and detect colon cancer earlier by practicing early detection through screening. CRC screening tests available now include #Cologuard and Colonoscopy The cfDNA is a blood test and another tool we can use in our primary prevention strategy #CRC #coloncancerscreening #preventionisbetterthancure #yourhealthmatters

Did you know? Recent studies published in Nature, 2024, have identified a specific clade of oral bacteria—Fusobacterium nucleatum subspecies animalis (Fna) C2—as dominant in individuals with colorectal cancer. This pivotal discovery could revolutionize how we detect and treat one of the most serious types of cancer. 🧬✨ Curious about your oral microbiome and its secrets? Explore your health with Prism’s Oral Health Test—simple, insightful, and directly from home. Link in bio. ☝️ PMID: 38509359 #OralHealth #ColorectalCancerAwareness #MicrobiomeResearch #CancerPrevention #HealthInnovation #PrismHealth #HomeHealthTest #NatureJournal #CuttingEdgeScience #HealthyLiving #Gingivitis #BadBreath #DentalCare #WellnessJourney #HealthTech

How precision medicine is tackling cancer

Today we observe #WorldHepatitisDay The #liver is one of the most important organs which is vital to a healthy life. However, increased liver fat content is well known to lead to steatohepatitis, cirrhosis, and even cancer. Fat imaging and quantification can simultaneously, in a single breath hold #MRI exam, provide quantitative maps of the liver to measure proton density fat fraction (PDFF) and R2*. In our Good to Know series we present how Canon’s FFQ technology can help to quantify a patient’s liver fat concentration to accurately diagnose and stage disease, and to track disease progression. Watch the video or visit our website to learn more! Website Link https://bit.ly/3cPxOiA #MadePossible #GoodToKnow #NAFLD #NASH

Lung cancer webinar 🫁 Join us for our interactive webinar in partnership with Agilio Software | Primary Care on Wednesday 28th August, and enhance your #lungcancer early diagnosis knowledge.  Secure your place 👉 https://bit.ly/3Ao4VFU What will be covered? ➡ Presentation ➡ Family history  ➡ Primary care investigations  ➡ Lung cancer in never-smokers  ➡ Targeted lung health checks Suitable for primary care professionals in England. #Lungcancer #earlydiagnosis #primarycare

Leading to kidney enlargement and eventual loss of function, autosomal dominant polycystic kidney disease (ADPKD) affects more than 12 million people worldwide. Now, a potential solution is on the horizon. Researchers at MIT and the Yale University School of Medicine, including MIT research scientist Bogdan Fedeles, have identified a compound, originally developed to treat cancer, that holds promise for treating ADPKD. Fedeles explained, “We really believe this has potential to impact the field and provide a different treatment paradigm for this important disease.” 🔗 Read the full article: https://bit.ly/3W6SxT4 📷: Melanie Gonick, MIT ✍️: Anne Trafton, MIT News #MITNews #MITResearch #Healthcare #Medicine #Science

❗ A systematic review of 33 papers involving >250,000 patients reported that >85% of patients were more satisfied and confident following the second medical opinions 🚩 Substantial discrepancies between the first and second opinions in diagnosis and suggested treatment were reported across the studies. A few snippets here: Eyes: Treatment change in 56% of patients Lung cancer: Fist and second opinion discrepancy in 80% of patients, of which 58% had a potential major impact on survival, morbidity and quality of life All cancer: Treatment change in 42% of patients General medicine: Treatment change in 45% of patients 🕯 At OptimisHealth, we use big data to to help you identify the top medical experts at the top of their game so you can be confident in the care you receive www.optimishealth.net #healthawareness #secondmedicalopinion #bigdata #healthtransparency

Medical College of Wisconsin #cancer researchers from the Drobyski, Hillard, and Zamora labs may have found a way to prevent neuroinflammation in patients with graft versus host disease (GVHD)—a major complication in those undergoing allo-HSCT—by targeting a receptor called CB2R. Results of their study, recently published in The Journal of Clinical Investigation, could lead to new treatments that help prevent neuroinflammation caused by GVHD, as well as other T cell-based immunotherapeutic approaches. Learn more: https://lnkd.in/gWJScHBf #cancerresearch #CancerDiscovery #cancertreatment #GVHD #immunotherapy #precisionmedicine

🌟 Check out our top pick of the day! 🌟 📢 Groundbreaking Research Brings New Hope for Patients with Rare Abdominal Cancer Read more here: https://lnkd.in/dAAMW7fg 🔍 Stay informed with the best health insights and updates. Don't miss out! 🚀 #HealthNews #TopPick #medicalnews